Clinical trial

First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)

NCT03189719

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2017-07-25

PhasePHASE3

Study timeline

Study start (actual)2017-07-25Date precision: day

Registry last updated2024-10-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Esophageal Neoplasmsunresolved

Interventions

PembrolizumabBIOLOGICAL

PlaceboDRUG

CisplatinDRUG · verified · RxNorm: cisplatin

5-FUDRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Mapped research locations

SeoulSouth Korea4 Hong KongHong Kong4 BangkokThailand4 ShanghaiChina3 IstanbulTurkey (Türkiye)3 TokyoJapan3 MadridSpain2 TaipeiTaiwan2 MoscowRussia2 Saint PetersburgRussia2 Buenos AiresArgentina2 TaichungTaiwan2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03189719 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.